<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2215">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04395911</url>
  </required_header>
  <id_info>
    <org_study_id>SCD-005</org_study_id>
    <nct_id>NCT04395911</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections</brief_title>
  <official_title>A Multi-Center Pilot Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device (SCD) in Patients Developing Acute Kidney Injury (AKI) or Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SeaStar Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SeaStar Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Selective Cytopheretic Device (SCD) treatments will improve survival in patients testing
      positive for COVID-19 infection diagnosed with Acute Kidney Injury (AKI) or ARDS.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality at Day 60</measure>
    <time_frame>60 days post treatment</time_frame>
    <description>All cause mortality at Day 60</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dialysis Dependency</measure>
    <time_frame>60 days post treatment</time_frame>
    <description>Dialysis Dependency at Day 60</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventilation at Day 28</measure>
    <time_frame>28 days post treatment</time_frame>
    <description>Ventilation free survival at Day 28</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dialysis Dependency</measure>
    <time_frame>28 days post treatment</time_frame>
    <description>Dialysis Dependency at Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality at Day 28</measure>
    <time_frame>28 days post treatment</time_frame>
    <description>All cause mortality at Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary output change</measure>
    <time_frame>10 days of treatment</time_frame>
    <description>Change from baseline in urine output</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P02/FiO2 change</measure>
    <time_frame>10 days of treatment</time_frame>
    <description>Change from baseline in PO2/FiO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Assessments</measure>
    <time_frame>10 days of treatment</time_frame>
    <description>Assessment of SAEs, AE and UADEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCD Integrity</measure>
    <time_frame>10 days of treatment</time_frame>
    <description>Assessment of device performance</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>AKI</condition>
  <condition>ARDS</condition>
  <condition>COVID</condition>
  <arm_group>
    <arm_group_label>SCD</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cytopheretic device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SCD</intervention_name>
    <description>cytopheretic device</description>
    <arm_group_label>SCD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent obtained

          -  Positive COVID-19 test

          -  Must be receiving medical care in an intensive care nursing situation

          -  Non-pregnant females

          -  Intent to deliver full supportive care through aggressive management utilizing all
             available therapies for a minimum of 96 hours.

          -  Platelet count &gt;30,000/mm3 at Screening

          -  Clinical diagnosis of AKI requiring CRRT or ARDS

        Exclusion Criteria:

          -  Cardiovascular instability that precludes initiation of continuous renal replacement
             therapy (CRRT).

          -  Irreversible brain damage based on available historical and clinical information.

          -  Presence of any solid organ transplant at any time.

          -  Patients with stem cell transplant in the previous 100 days or who have not engrafted.

          -  Acute or chronic use of circulatory support device other than ECMO such as LVADs,
             RVADs, BIVADs.

          -  Metastatic malignancy which is actively being treated or may be treated with
             chemotherapy or radiation during the subsequent three month period after study
             treatment.

          -  Chronic immunosuppression defined as &gt;20 mg prednisone qd alone without other
             immunosuppressant medications (ie (cyclophosphamide, azathioprine, methotrexate,
             rituximab, mycophenolate, cyclosporine).

          -  Patient is moribund or chronically debilitated for whom full supportive care is not
             indicated.

          -  Concurrent enrollment in another interventional clinical trial. Patients enrolled in
             observational studies (NO TEST DEVICE OR DRUG USED) are allowed to participate.

          -  Any reason the Investigator deems exclusionary.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eric Schlorff</last_name>
    <phone>844-427-8100</phone>
    <email>Eric@seastarmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier N Lozano, MD</last_name>
      <phone>859-218-0932</phone>
      <email>jne255@uky.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 17, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2020</study_first_posted>
  <last_update_submitted>September 11, 2020</last_update_submitted>
  <last_update_submitted_qc>September 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Unidentified participant data collected for this study will be submitted to a CRO for data analysis. All data will be submitted to the Sponsor.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will be collected throughout the study conduct.</ipd_time_frame>
    <ipd_access_criteria>Participant data will be accessible to the Investigational Site and CRO through a secured electronic data capture system. CRO personnel will be responsible for data verification. De-identified Participant information will be accessible to the CRO and the Sponsor.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

